And this is where targeted radiotherapeutics come in. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr ...

Inizio brings in seasoned pharma exec for top job. A new chapter begins at Inizio with the appointment of Ryan Quigley as CEO ...

ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies ...

Inherited cardiac conditions (ICCs) can lead to heart failure, and fewer than half of all people diagnosed with heart failure ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Thermo Fisher Scientific has agreed to acquire Clario Holdings for nearly $8.9 billion in cash, in a deal that would give it ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Prostate Cancer UK started a £42 million ($55 million), large-scale study called TRANSFORM last year to test that MRI-refined ...

Lilly moved first. In January 2024, it launched LillyDirect, linking patients with telehealth providers and home delivery for its diabetes and weight-management portfolio. Pfizer followed in August ...

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilars to market, in a bid to accelerate the rollout of cheaper versions of off-patent biologic drugs. Draft ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...